Welcome to our dedicated page for MASIMO SEC filings (Ticker: MASI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MASIMO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MASIMO's regulatory disclosures and financial reporting.
Masimo Corporation’s major shareholder Politan Capital has updated its ownership filing after a merger announcement with Danaher. Politan and related entities report beneficial ownership of 4,590,873 Masimo common shares, representing 6.2% of the company, based on 74,218,782 shares outstanding as of February 13, 2026.
Masimo agreed to a merger in which a Danaher subsidiary will combine with Masimo, leaving Masimo as a wholly owned Danaher subsidiary. In connection with this, Politan entered into a Voting and Support Agreement committing to vote its Masimo shares in favor of adopting the merger agreement and approving the merger, and agreeing to customary transfer restrictions.
The filing notes that no Masimo share transactions were made by the reporting persons in the past 60 days and that a portion of their holdings is pledged under a standard margin loan facility.
Danaher Corporation plans to acquire Masimo Corporation in an all-cash deal valuing Masimo at $180 per share, or about $9.9 billion in enterprise value including assumed debt and net of cash. Masimo is a leading provider of pulse oximetry and other patient monitoring technologies, mainly for acute care.
Masimo will operate as a standalone business within Danaher’s Diagnostics segment alongside brands such as Radiometer and Beckman Coulter Diagnostics. Danaher expects Masimo to deliver high-single digit core revenue growth over the long term and to generate more than $530 million of EBITDA in 2027.
The acquisition is projected to increase Danaher’s adjusted diluted net earnings per share by $0.15–$0.20 in the first full year and about $0.70 in the fifth full year. Danaher also targets over $125 million in annual cost synergies and more than $50 million in annual revenue synergies by the fifth full year. Closing is anticipated in the second half of 2026, subject to regulatory clearances and Masimo shareholder approval, and will be funded with cash on hand and new debt.
Masimo Corporation agreed to be acquired by Danaher Corporation in an all-cash merger valuing Masimo at $180.00 per share, or about $9.9 billion. Masimo will become a standalone business unit within Danaher’s Diagnostics segment and continue operating under the Masimo brand.
The deal requires approval from Masimo stockholders, antitrust and foreign investment clearances, and other customary closing conditions. A voting agreement with Politan Capital Management supports the merger, and Masimo could owe Danaher a $305 million termination fee in certain scenarios. Closing is expected in the second half of 2026, after which Masimo’s shares will be delisted and deregistered.
Masimo Corporation: Joe Kiani reports beneficial ownership of 5,904,629 shares of common stock, representing 10.3% of the class as calculated in the filing. The reported total combines issued shares and multiple equity awards that the filer says remain issuable but which the company has not issued.
The filing details that 368,252 shares relate to exercised options the company declined to process and that the filer includes 2,700,000 RSUs, 158,450 accelerated options, 198,225 PSUs, and 85,255 vested options among the components of the aggregate beneficial ownership; several of those items are subject to a dispute described in footnotes.
Masimo Corporation CEO Catherine M. Szyman reported equity compensation activity on February 12, 2026. She exercised 11,141 restricted stock units (RSUs), converting them into 11,141 shares of common stock at a price of $132.96 per share. Of these, 4,568 shares were withheld by Masimo to cover tax withholding obligations tied to the vesting of performance RSUs, leaving her with 6,573 shares of common stock held directly. Following the transaction, she also directly held 22,283 RSUs, which continue to represent the right to receive an equal number of common shares upon future vesting.
Masimo Corporation executive Sampath Anand, EVP of Ops & Clinical Research, exercised stock options and sold shares of common stock. On January 28, 2026, he exercised 30,000 non-qualified stock options at an exercise price of $37.84 per share, receiving 30,000 shares.
That same day he sold Masimo common stock in three transactions under a Rule 10b5-1 sales plan dated September 12, 2025. He sold 11,924 shares at a weighted average price of $136.56, 6,560 shares at $137.22, and 196 shares at $138.09. Following these transactions, he directly owned 40,909 Masimo shares.
Masimo Corporation has received a notice under Rule 144 for the proposed sale of 18,680 shares of its common stock through broker Charles Schwab & Co., Inc. on NASDAQ. The aggregate market value of the shares listed for sale is $2,555,567.00.
The seller acquired the 18,680 shares on 01/28/2026 through an employee stock option exercise, with a broker-facilitated cashless exercise used as payment. The filing notes that 53,713,949 common shares are outstanding and includes standard representations about the absence of undisclosed material adverse information.
BlackRock Portfolio Management LLC filed an amended Schedule 13G reporting its beneficial ownership of MASIMO CORPORATION common stock as of 12/31/2025. The firm reports beneficial ownership of 4,386,302 shares of common stock, representing 8.2% of the outstanding class. It has sole power to vote 4,290,570 shares and sole power to dispose of 4,386,302 shares, with no shared voting or dispositive power.
The filing explains that the shares are held by certain business units of BlackRock, Inc. and affiliates, and that various underlying persons have rights to dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares. BlackRock Portfolio Management LLC certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Masimo.
Masimo Corporation filed an 8-K describing how it is sharing early views of its recent performance. On January 12, 2026, the company issued a press release with select preliminary financial results for the fourth quarter and full year ended January 3, 2026, with full audited figures to follow.
Management plans to review complete fourth quarter and full-year 2025 results after the market closes on February 26, 2026. On the same day as the filing, the CEO and EVP & CFO discussed select preliminary results at the 44th Annual J.P. Morgan Healthcare Conference, and Masimo also made available a supplemental 2025 earnings presentation and non-GAAP information as furnished exhibits.
Masimo Corporation (MASI) reported an insider equity transaction by its CTIO and EVP of Engineering on November 13, 2025. A previously granted award of 2,474 restricted stock units (RSUs), originally granted on November 13, 2024, vested in full and was converted into the same number of shares of common stock. To cover tax withholding obligations tied to this vesting, 974 shares were withheld by the company at a stated price of $152.43 per share for the acquisition transaction and $0 for the tax withholding entry. Following these transactions, the officer directly held 3,268 shares of Masimo common stock, reflecting the updated beneficial ownership after the RSU vesting and tax withholding.